It’s the second most common autoimmune disease affecting 4 million Americans—and now a new study is shedding more light on the development and life cycle of Sjögren's syndrome.
The research published from the Forsyth Institute and published in Scientific Reports is groundbreaking in that it’s the first to define the immune regulatory mechanisms operating in Sjögren's syndrome, and provides new insight into fighting the disease.

Severe dry mouth is one of the most noticeable signs of Sjogren’s Syndrome, and many patients who suffer from this disease are treated with NeutralSal by OraPharma.

To learn more about the study and its implications, click here.